Biopharmaceutical company UCB (Euronext Brussels:UCB) announced on Thursday that it has launched a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX (bimekizumab-bkzx).

This is in addition to the currently available 1 ml device administration option, each containing 160 mg of the product. With the new device, patients requiring a 320 mg dose of BIMZELX will have the option of single-injection administration.

The approval of the 320 mg single-injection administration option in October 2024 was supported by data from studies evaluating the bioequivalence of BIMZELX 320 mg given as one 2 mL subcutaneous injection, and BIMZELX 320 mg given as two 1 mL subcutaneous injections, in healthy study participants.

Through BIMZELX Navigate, UCB offers tailored patient support to patients who have been prescribed BIMZELX. Upon enrolment, patients will be offered support from a dedicated Nurse Navigator. This licensed, registered nurse will be available to discuss treatment goals, provide training assistance to patients on how to administer BIMZELX, connect eligible patients to copay support, and keep patients up-to-date about their BIMZELX shipment and insurance coverage status.